Alentis Therapeutics: Alentis Founder Receives Prestigious French Academy of Science Award
Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201222005253/en/
Professor Thomas Baumert, founder of Alentis Therapeutics. Copyright Alentis Therapeutics
Said Prof. Thomas Baumert: It s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly benefit.